People
Robert Redfield, director of the U.S. Centers for Disease Control and Prevention, testified yesterday before the U.S. Senate Appropriations subcommittee on labor, health and human services, education and related agencies.
The study, led by U.S. researchers, showed that the novel system was safe and effective for managing blood glucose in children as young as 6 years old.
One company working towards an ARDS treatment is Athersys, a biotech company focusing on regenerative medicine therapies for diseases with significant unmet need.
Although it is increasingly likely that one of the COVID-19 vaccines currently being tested will be approved or receive Emergency Use Authorization before the end of the year, experts are increasingly warning that widespread distribution may take a much longer time.
The company is genetically programming RNA not just to deliver a gene of interest, but to control the location, timing and intensity of therapeutic protein expression using mRNA-encoded logic circuits.
Orasis Pharmaceuticals has closed on $30 million dollars in Series C financing that will propel its corrective eye drop candidate for presbyopia symptoms, CSF-1, through Phase III clinical trials.
Six months into a global pandemic and public trust is waning in its support for public health officials in charge of the nation’s response to the novel coronavirus, according to a new poll.
Despite a temporary pause on its COVID-19 vaccine trial, AstraZeneca Chief Executive Officer Pascal Soriot said the preventative drug could still be available for commercial use by the end of the year, or in early 2021 barring any other setback.
Elizabeth Holmes, the founder and former chief executive officer of failed diagnostics company Theranos, will be examined by a psychologist and psychiatrist ahead of her looming trial for fraud.
Biopharma and life sciences companies bolster their leadership teams and boards with these Movers & Shakers.
PRESS RELEASES